Amycretin is the quietest big story in obesity pharmacology. In December 2024, Novo Nordisk disclosed Phase 1 data showing that a once-daily oral peptide delivered roughly 13% placebo-adjusted weight loss over 12 weeks — a figure that, extrapolated linearly, would put it ahead of every currently approved obesity drug. It is a single molecule that agonizes both the GLP-1 receptor and the amylin receptor, and it comes as a pill. This article examines what amycretin actually is, why its route of administration is a bigger deal than its efficacy, and where it sits in Novo Nordisk's pipeline chess game with Eli Lilly.
⚕️ Regulatory & Safety Notice
Amycretin is investigational. As of early 2026 it is in Phase 2 development for obesity and type 2 diabetes. It is not approved by any regulatory agency, not available by prescription, and not available in any compounding channel. All data in this article is from Novo Nordisk investor disclosures and peer-reviewed Phase 1 reporting. Nothing here is medical advice.
What Is Amycretin?
Amycretin is a unimolecular dual agonist — a single engineered peptide that activates two different receptors. Specifically, it acts as an agonist at both the GLP-1 receptor (the target of semaglutide, liraglutide, tirzepatide's GLP-1 arm, and the entire incretin class) and the amylin receptor family (the target of pramlintide and Novo's own injectable amylin analog cagrilintide). Unlike CagriSema, which combines two separate molecules (cagrilintide + semaglutide) in a fixed-dose co-formulation, amycretin folds both activities into a single peptide backbone.
The technical achievement is twofold. First, designing one amino acid sequence that can engage two structurally distinct receptor families without losing affinity at either. Second — and this is the harder part — engineering that sequence to survive the gastrointestinal tract and absorb through the stomach wall in sufficient quantities to produce a pharmacological effect after an oral dose.
Amycretin comes in both oral and subcutaneous formulations in Novo Nordisk's pipeline, but the oral version is the strategically interesting one.
Mechanism
The mechanistic rationale for a dual GLP-1/amylin agonist is strong. GLP-1 receptor agonism slows gastric emptying, enhances glucose-dependent insulin secretion, and — most importantly for obesity — acts centrally on hypothalamic and brainstem circuits to suppress appetite and reduce food reward. This is the mechanism that made semaglutide the most commercially successful drug in history. For the underlying biology, see our explainer on how GLP-1 drugs work.
Amylin receptor agonism does something different but complementary. Amylin is a peptide co-secreted with insulin from pancreatic beta cells. It slows gastric emptying, suppresses glucagon, and — critically — acts on the area postrema and hypothalamus to produce satiety through a distinct signaling pathway from GLP-1. In clinical studies of cagrilintide (Novo's selective amylin analog), the weight loss mechanism appears to be additive to, not redundant with, GLP-1 agonism. Patients who plateau on semaglutide continue losing weight when cagrilintide is added, suggesting the two satiety pathways converge on food intake from different directions.
Amycretin is essentially the pharmacological bet that these two pathways can be fused into one molecule. Early receptor binding data suggest comparable potency at both targets.
The oral delivery piece is a formulation problem, not a receptor problem. Peptides are normally destroyed by gastric acid and pepsin, then degraded further by brush-border peptidases, and what survives is too polar and too large to cross the intestinal epithelium efficiently. Novo Nordisk solved most of these problems for oral semaglutide (Rybelsus) using SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), a small molecule that transiently fluidizes the gastric mucosa and raises local pH to protect the peptide during absorption. Amycretin uses a related but further-refined absorption enhancer strategy. Bioavailability is still low — likely in the single-digit percent range — but high enough to achieve therapeutic plasma levels with a daily dose that fits in a pill.
Evidence
The foundational dataset is a Phase 1 single ascending dose and multiple ascending dose study reported by Novo Nordisk in December 2024 at its Capital Markets Day and subsequently published in peer-reviewed form (Enebo et al., 2024, The Lancet). The study randomized healthy adults with overweight or obesity to oral amycretin or placebo, escalated through dose cohorts, and reported safety, pharmacokinetics, and — as an exploratory endpoint — body weight change.
At the highest dose tested over 12 weeks, participants on oral amycretin lost approximately 13.1% of body weight compared to placebo. In a Phase 1 study with short duration and limited statistical power, linear extrapolation is dangerous, but the trajectory is striking because semaglutide in STEP-1 took roughly 68 weeks to reach 14.9% mean weight loss. If amycretin's early slope holds — a real "if" — it would be best-in-class.
Subcutaneous amycretin data reported at the same time showed even larger effect sizes, approximately 22% weight loss over 36 weeks at the top dose, though that is a different trial arm with different dose ranges and durations.
Side-effect profile in Phase 1 was broadly consistent with the GLP-1 class: nausea, vomiting, decreased appetite, and transient GI symptoms that tended to improve with continued dosing. Nothing off-class was flagged, but 12 weeks in healthy volunteers is not the dataset that establishes long-term safety.
Applications and Strategic Context
The obvious application is obesity and type 2 diabetes, where amycretin enters a market that Novo Nordisk and Eli Lilly have essentially split between them. What makes amycretin strategically distinctive is the oral route.
Why oral matters, in five points.
-
Manufacturing constraints. Injectable GLP-1 demand has outstripped global peptide manufacturing capacity repeatedly since 2022. Oral delivery via tablet compression is an entirely different supply chain than sterile injectable fill-finish. It scales differently, costs less per dose at volume, and decouples Novo's obesity franchise from sterile manufacturing bottlenecks.
-
Patient preference and adherence. A pill is easier to start, easier to continue, and carries less stigma than a weekly injection. This matters most for the large cohort of patients with obesity who would never accept an injection for a non-acute condition.
-
Global access. Cold-chain distribution and injection training are the two largest barriers to deploying injectable peptides in middle-income countries. A shelf-stable daily oral tablet is a fundamentally different global health product.
-
Defensive IP. Eli Lilly's main oral competitor is orforglipron, a non-peptide small-molecule GLP-1 agonist. Orforglipron is chemically simpler and cheaper to manufacture, but it is a pure GLP-1 agonist without amylin activity, and its clinical efficacy so far looks comparable to injectable semaglutide rather than superior to it. If amycretin's dual-agonist efficacy holds, Novo can argue that oral peptides remain the best-in-class platform despite the manufacturing overhead.
-
Pricing and reimbursement leverage. Payers have been increasingly aggressive about limiting GLP-1 coverage for obesity alone. Differentiated efficacy in an oral formulation is the kind of data Novo needs to defend premium pricing in the face of orforglipron's impending launch and generic semaglutide on the horizon.
Market reaction after the December 2024 Phase 1 disclosure was predictably sharp: Novo Nordisk's share price jumped meaningfully the day of the announcement and again as peer-reviewed data followed. The overhang through 2025 has been the question of whether Phase 2 would confirm the Phase 1 slope or reveal a more modest steady-state effect. Phase 2 results are expected to read out through 2026 and 2027.
Amycretin sits alongside CagriSema (the two-molecule fixed-dose injectable) and semaglutide 7.2 mg in Novo's obesity pipeline, and against retatrutide (Lilly's triple GIP/GLP-1/glucagon agonist) externally. It is Novo's clearest oral-peptide bet for the next decade.
Connection to Gene Editing
Amycretin is a peptide therapeutic, not a gene-editing product, but the two fields intersect at a specific and increasingly important question: why administer a therapeutic daily when you could instruct the body to produce its own?
Several gene therapy and RNA programs are now exploring long-acting GLP-1 analog expression from a single administration. AAV-delivered expression cassettes encoding GLP-1 fusion proteins have shown efficacy in rodent models of obesity and diabetes, producing sustained circulating peptide levels for months from one injection. CRISPR-based approaches aim higher: editing the liver to secrete engineered satiety peptides, or modulating endogenous appetite circuits directly. For the underlying technology, see what is CRISPR.
This creates a tension amycretin both answers and intensifies. If oral daily dosing can deliver best-in-class efficacy with a flexible, stoppable safety profile, the case for a permanent gene-therapy intervention in obesity becomes harder to make — the benefit-risk ratio of a one-shot, irreversible change has to clear a much higher bar than a pill you can discontinue. On the other hand, every patient who achieves 15–20% weight loss with amycretin and then experiences weight regain upon discontinuation becomes a potential candidate for a durable, single-administration intervention. The two modalities are racing toward the same metabolic-disease patient population from different directions.
The peptide engineering that made amycretin possible also feeds directly into the protein-design pipeline for gene-therapy payloads. The same dual-receptor engagement logic can, in principle, be encoded in a secreted fusion protein delivered by AAV. Novo Nordisk's decade of amylin and incretin peptide optimization is, in this sense, a library of validated sequences that could eventually be expressed rather than injected.
Limitations
Several caveats belong in front of any patient or investor conclusion about amycretin.
The Phase 1 data is Phase 1 data. Twelve weeks in healthy volunteers. Effect sizes in obesity trials routinely shrink from Phase 1 to Phase 3 as larger, more heterogeneous populations dilute the mean and real-world discontinuation rates climb. A 13% Phase 1 number could easily translate to 15–18% in Phase 3, which is still excellent, or to a number that looks disappointingly similar to semaglutide.
Oral bioavailability is fragile. Food, fluid intake, gastric pH, and concomitant medications all affect how much amycretin actually reaches the systemic circulation. Rybelsus has complicated dosing instructions (fasting, 30 minutes before food, with limited water) precisely because of this. Real-world adherence to these instructions is imperfect.
GI side effects remain the dose-limiting toxicity. As with all dual agonists, the effective dose and the tolerable dose often overlap uncomfortably.
Long-term safety is unknown. Amycretin has not been dosed in humans long enough to characterize risks around muscle mass loss, gallbladder disease, pancreatitis, or the other GLP-1 class effects that have accumulated over years of semaglutide data. See also GLP-1 and muscle loss.
Commercial success is not guaranteed by efficacy. Orforglipron's manufacturing cost advantage may matter more to payers than a few percentage points of weight loss difference.
FAQ
Is amycretin available now?
No. Amycretin is in Phase 2 clinical development and is not approved by the FDA, EMA, or any other regulator. It cannot be prescribed, compounded, or legally sold as of early 2026.
How is amycretin different from CagriSema?
CagriSema is a fixed-dose co-formulation of two separate peptides (cagrilintide and semaglutide) delivered as a single injection. Amycretin is one peptide that activates both the GLP-1 and amylin receptors. Amycretin is also being developed in an oral formulation; CagriSema is injectable only.
How does amycretin compare to tirzepatide?
Tirzepatide (Mounjaro/Zepbound) is an injectable dual GLP-1/GIP agonist. Amycretin is a dual GLP-1/amylin agonist with an oral formulation. GIP and amylin are different receptors driving overlapping but distinct effects. Head-to-head data does not yet exist.
Is oral amycretin as effective as the injectable version?
Early data suggests injectable amycretin produces larger absolute weight loss numbers than the oral form at matched durations, though the oral Phase 1 trajectory is still impressive. Exact comparisons will come from Phase 2 head-to-head arms.
How does amycretin compare to orforglipron?
Orforglipron is Eli Lilly's oral non-peptide GLP-1 agonist. It is chemically simpler (small molecule, not peptide), likely cheaper to manufacture, but acts only at GLP-1. Amycretin's dual mechanism theoretically produces greater weight loss; orforglipron's manufacturing profile theoretically enables lower pricing.
When will amycretin be available?
Assuming Phase 2 and Phase 3 readouts are positive, an FDA submission would likely come no earlier than 2028, with potential approval and launch in 2029 or 2030. This timeline could slip.
